Associated Papers
Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.
Ambrosini-Spaltro A et al.
Journal of Personalized Medicine, 2025
Identification and analysis of oncogenic non-synonymous single nucleotide polymorphisms in the human NRAS gene: An exclusive in silico study.
Mozibullah M et al.
Journal, Genetic Engineering & Biotechnology, 2024
38797553 (PubMed )
Supplement: mmc1.xlsx › Table_1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma.
Jiang H et al.
Frontiers in Oncology, 2021
35186718 (PubMed )
Supplement: Table_1.xlsx › Supplementary_Table_2
Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y et al.
Molecular Oncology, 2020
32478891 (PubMed )
Supplement: MOL2-14-1731-s002.xlsx › Sheet1
Select a paper to view details